Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan Oct 25, 2013 10:08 AM Flag

    S&P analyst positive about partnering VX 509 based on clinical trial data

    October 21, 2013
    09:42 am ET ... S&P CAPITAL IQ KEEPS BUY OPINION ON SHARES OF VERTEX
    PHARMACEUTICALS (VRTX 77.06****):We keep our $104 NPV-based target
    price. VRTX reports positive Phase IIb data for pipeline candidate JAK3 inhibitor
    VX-509 in rheumatoid arthritis.We see efficacy as promising, with statistically
    significant response improvements over placebo. Despite a higher adverse event
    rate over placebo, there were fewer discontinuations, and we think its safety is
    consistent with peers.We expect VRTX to out-license VX-509 for late-stage study
    and, despite an outlook for a competitive market, we view the rheumatoid arthritis
    market as lucrative and likely to attract partnering interest. /S.Silver

 
VRTX
81.90-6.30(-7.14%)Jun 24 4:00 PMEDT